Welcome to our dedicated page for MaxCyte news (Ticker: $MXCT), a resource for investors and traders seeking the latest updates and insights on MaxCyte stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect MaxCyte's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of MaxCyte's position in the market.
Rhea-AI Summary
MaxCyte, Inc. (MXCT) announces the retirement of President and CEO Doug Doerfler, effective December 31, 2023, and the appointment of Maher Masoud as the new President and CEO, effective January 1, 2024. MaxCyte reiterates 2023 expected core business revenue of $28-30 million and expects to exceed prior SPL program-related guidance with revenue of at least $10 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.39%
Tags
-
Rhea-AI Summary
MaxCyte, Inc. (Nasdaq: MXCT; LSE: MXCT) has joined the Alliance for mRNA Medicines (AMM) as a founding member, aiming to advance and advocate for mRNA and next-generation encoding RNA therapeutics and vaccines. The company's versatile electroporation platform continues to provide scientific innovators with a powerful and flexible transfection method to accelerate the development of critical medicines and vaccines. MaxCyte remains committed to enabling the development of new applications for mRNA technology. The AMM, comprised of 31 founding members, will advocate for policies that encourage innovation and funding, define regulatory and reimbursement standards, support manufacturing, and promote access to mRNA medicines to patients by educating and engaging with governments, policymakers, regulators, and other stakeholders in North America, Europe, and Asia Pacific.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.28%
Tags
-
News
Rhea-AI Summary
MaxCyte, Inc. (MXCT) Announces Third Quarter 2023 Financial Results, Revenue Decline, and Full Year Guidance. Despite challenges, the company remains confident in the long-term potential of the cell and gene therapy market.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.28%
Tags
Rhea-AI Summary
MaxCyte, Inc. will participate in two upcoming investor conferences, including the Stifel 2023 Healthcare Conference Fireside Chat on November 15th and the Stephens Annual Investment Conference Fireside Chat on November 16th. The events will be webcasted live and archived on the MaxCyte investor relations website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.86%
Tags
-
News
Rhea-AI Summary
MaxCyte, Inc. announces preliminary Q3 2023 revenue of $7.8-8.0 million, a decrease of 25-27% compared to Q3 2022. Core business revenue decreased by 33-35%. SPL Program-related revenue increased to $1.4 million. Full year revenue guidance updated to approximately $34-36 million. Core revenue expected to be $28-30 million. SPL Program-related revenue expected to be $6 million. CEO cites reduced customer activity and funding environment as reasons for decline. Company remains optimistic about long-term prospects.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-20.64%
Tags
-
Rhea-AI Summary
MaxCyte appoints Ali Soleymannezhad as EVP of Bioprocessing
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
MaxCyte, Inc. to participate at Baird Global Healthcare Conference on September 13th.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.35%
Tags
-
Rhea-AI Summary
MaxCyte, Inc. announces Q2 2023 financial results. Total revenue of $9.0M, a decrease of 6% compared to Q2 2022. Core business revenue of $8.3M, a decrease of 14%. Five strategic partnerships signed year-to-date. Total cash, cash equivalents, and short-term investments of $216.1M as of June 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.44%
Tags
-
Rhea-AI Summary
MaxCyte, Inc. (Nasdaq: MXCT; LSE: MXCT) partners with Prime Medicine, Inc. to advance Prime Editing technology using Flow Electroporation® and ExPERT™ platform. Prime Medicine gains non-exclusive clinical and commercial rights, paying annual license fees and program-related revenue. MaxCyte's President and CEO, Doug Doerfler, expresses excitement for the partnership and Prime Medicine's innovative vision. Prime Medicine aims to develop one-time, potentially curative genetic therapies using their Prime Editing platform, while MaxCyte's ExPERT™ instrument portfolio provides the necessary cell engineering technology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.67%
Tags
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.6%
Tags
MaxCyte, Inc.
Nasdaq:MXCT
MXCT Rankings
MXCT Stock Data
394.04M
91.50M
1.3%
76.37%
3.13%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
United States of America
ROCKVILLE
About MXCT
MaxCyte is a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization.